(S039) High-Resolution 4D Ventilation and Perfusion PET/CT Facilitates Functionally Adapted Intensity-Modulated Radiation Therapy (IMRT) in Lung Cancer

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

IMRT plans that were adapted to perfused but not ventilated lung on 4D-V/Q PET/CT allowed for reduced dose to the functional lung while maintaining consistent plan quality.

David Ball, MD; Peter MacCallum Cancer Centre

PURPOSE: To assess the utility of functional lung avoidance using intensity-modulated radiation therapy (IMRT) informed by four-dimensional ventilation/perfusion positron emission tomography/computed tompgraphy (4D-V/Q PET/CT) in patients with non–small-cell lung cancer (NSCLC).

MATERIALS AND METHODS: In a prospective clinical trial, patients underwent 4D-V/Q PET/CT scanning before 60 Gy of definitive chemoradiation. Both “highly perfused” (HPLung) and “highly ventilated” (HVLung) lung volumes were delineated using a visually adapted 70th percentile standardized uptake value (SUV) threshold method. The HVLung was universally smaller than HPLung; so, a “ventilated lung volume” (VLung) was created to approximate the HPLung using a 50th percentile SUV threshold. For each patient, four IMRT plans were created, optimized to the anatomical lung, HPLung, VLung, and HPLung volumes. IMRT that was optimized to the anatomical lung was compared with functionally adapted IMRT using functional lung volumetrics, including mean lung dose (MLD), V5, V10, V20, V30, V40, V50, and V60 parameters. Plan quality was assessed by dose to 95% and 5% of planning target volume (PTV) (D95 and D5), conformity index (CI), and heterogeneity index (HI).

RESULTS: The study cohort consisted of 20 patients with 80 IMRT plans. The mean (+/– SD) lung volume for the HPLung and VLung was similar at 1,876 cc (+/– 677 cc) and 1,904 cc (+/– 505 cc), respectively, while HVLung was smaller at 932 cc (+/– 258 cc). Plans that were optimized to HPLung resulted in a significant reduction of functional MLD by a mean of 13.0% (1.7 Gy; P = .02). Functional V5, V10, and V20 were improved by 13.2%, 7.3%, and 3.8%, respectively (P < .04). There was no sparing of dose to functional lung when adapting to VLung or HVLung. Plan quality was highly consistent with a mean PTV D95 and D5, ranging from 60.8–61.0 Gy and 63.4–64.5 Gy, respectively, and with mean CI and HI ranging from 1.11–1.17 and 0.94–0.95, respectively.

CONCLUSIONS: IMRT plans that were adapted to perfused but not ventilated lung on 4D-V/Q PET/CT allowed for reduced dose to the functional lung while maintaining consistent plan quality.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content